SMH
ALXN

Sanders Morris Harris’s Alexion Pharmaceuticals ALXN Stock Holding History

Sanders Morris Harris’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,400
Closed -$627K – 341
2021
Q2 		$627K Hold
3,400
– – 0.12% 138
2021
Q1 		$518K Hold
3,400
– – 0.11% 149
2020
Q4 		$532K Hold
3,400
– – 0.12% 150
2020
Q3 		$421K Buy
3,400
+1,000
+42% +$108K 0.11% 167
2020
Q2 		$270K Buy
+2,400
New +$255K 0.13% 86

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Sanders Morris Harris's ALXN Position: Q3 2021 in Review

Sanders Morris Harris sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 3,400 shares — an estimated $627K sold.

Sanders Morris Harris first reported a position in ALXN in Q2 2020 and held it in 5 quarters. The position peaked at $627K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Sanders Morris Harris reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Sanders Morris Harris sold 3,400 Alexion Pharmaceuticals shares in Q3 2021, an estimated $627K.
  • Sanders Morris Harris first reported a position in Alexion Pharmaceuticals in Q2 2020 and held it in 5 quarters.
  • Sanders Morris Harris's Alexion Pharmaceuticals position peaked at $627K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Sanders Morris Harris's 13F filing for Q3 2021, filed 13 Oct 2021.